donor-derived Treg cell + interleukin 2

This therapy is a combination of adoptively transferred donor-derived regulatory T cells (Tregs) and exogenous interleukin 2 (IL-2) administration. Donor-derived Tregs are immunosuppressive cells that play a critical role in maintaining immune tolerance and preventing excessive immune responses. When administered to recipients—often in the context of transplantation or autoimmune disease—these cells can suppress alloreactive or autoreactive effector T cells, thereby reducing the risk of graft rejection or autoimmunity[1][6][7]. Interleukin 2 is a cytokine essential for the survival, proliferation, and function of regulatory T cells; low-dose IL-2 preferentially expands and enhances the function of these infused donor-derived Tregs without broadly activating effector immune responses[1][2][5]. The combination has shown synergistic effects in preclinical models by prolonging transplant survival more effectively than either component alone[1]. This approach is under investigation primarily for prevention or treatment of graft-versus-host disease (GVHD), solid organ transplant rejection, and certain autoimmune diseases[3][4].

Other names

donor-derived regulatory T cell + interleukin 2donor Treg + IL-2adoptive transfer of donor-derived Treg with IL-2